Here, we sought to determine whether the cardiac defects in SHP2Y279C/+ mice could be reversed by treatment with the upstream regulator of mTOR, AKT, by using a novel AKT inhibitor (ARQ 092) currently in clinical trials for patients with PI3K/AKT-driven tumors and Proteus syndrome [13]. Here, AKT1 is linked to Proteus syndrome.